Proactive Investors - Run By Investors For Investors

Abcam on track to meet its full-year target after posting top line growth of 11% in the first half

The company specialises in supplying antibodies and immunoassays to the life sciences research sector
researcher filling vials
The company continued to gain market share

Abcam PLC (LON:ABC), which supplies antibodies for research, said it is on track to meet its full-year 2019 financial targets after posting double-digit first-half growth.

In an update, it said revenues grew by 11% on a reported basis or 10% at constant at currencies.

READ: Abcam shares tumble as outlook misses expectations despite double-digit earnings growth in full year

Abcam said it continued to gain market share in the global research market, particularly in the areas of recombinant antibodies and immunoassays. Expansion in China has also helped underpin its success.

"Global demand is strong for precision life science tools and Abcam has once again gained market share in these growing markets.  Our business is on track to achieve double-digit growth for the year,” said chief executive Alan Hirzel.

"During the half, we have continued to focus on improving our service for customers.

“We have further developed our product portfolio and we have continued to enhance our organisational capabilities to support our ambition of becoming the most influential company for life scientists, supporting research, diagnostic and therapeutic discovery."

View full ABC profile View Profile

Abcam Timeline

January 10 2017

Related Articles

A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
Challenge trials can speed up vaccine development
May 30 2019
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use